论文部分内容阅读
目的探讨CA-125,CA-199,CEA测定在附件包块中的临床价值。方法测定157例附件包块患者及40例健康人的CA-125,CEA,CA-199值。结果卵巢癌组CA-125,CEA,CA-199值与良性附件包块各组及健康人组比较均有显著性差异(P<0.01),子宫内膜异位症,附件炎性包块组CA-125值与健康人组比较有显著性差异(P<0.01),良性附件包块各组CEA,CA-199值与健康人组比较均无显著性差异(P>0.05),三项联检卵巢癌总阳性率为96.8%。结论CA-125,CEA,CA-199是卵巢癌重要的相关抗原,在良恶性附件包块鉴别诊断中有重要意义,三项联检是一种早期诊断卵巢癌有效的方法。
Objective To investigate the clinical value of CA-125, CA-199 and CEA in the annex mass. Methods The CA-125, CEA and CA-199 values were measured in 157 cases with accessory mass and 40 healthy people. Results The levels of CA-125, CEA and CA-199 in ovarian cancer group were significantly different from those in benign adnexal mass group and healthy group (P <0.01). Endometriosis, There was significant difference between CA-125 and healthy subjects (P <0.01). There was no significant difference between CEA and CA-199 in benign appendages and normal controls (P> 0.05) The total positive rate of ovarian cancer was 96.8%. Conclusion CA-125, CEA and CA-199 are important antigens in ovarian cancer. They are important in the differential diagnosis of benign and malignant adnexal masses. The three combined tests are an effective method for early diagnosis of ovarian cancer.